Skip to Content
Find More Like This
Return to Search

Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG

United States Patent Application

20020169103
A1
View the Complete Application at the US Patent & Trademark Office
Brookhaven National Laboratory - Visit the Office of Technology Commercialization and Partnerships Website
The present invention relates to the use of gamma vinyl-GABA (GVG) and other GABAergic agents to treat obsessive-compulsive disorder (OCD) and OCD-related disorders, and to reduce or eliminate behaviors associated with obsessive-compulsive disorder (OCD) and OCD-related disorders.
Dewey, Stephen L. (Manorville, NY), Brodie, Jonathan D. (Cos Cob, CT), Ashby, Charles R. JR. (Miller Place, NY)
Brookhaven Science Associates LLC
10/ 175,576
June 20, 2002
[0001] This invention was made with Government support under contract number DE-AC02-98CH10886, awarded by the U.S. Department of Energy. The Government has certain rights in the invention.